Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Dexcom (DXCM) Tax Provisions (2016 - 2025)

Dexcom (DXCM) has disclosed Tax Provisions for 11 consecutive years, with $73.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Tax Provisions rose 23.15% to $73.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $252.1 million, a 89.83% increase, with the full-year FY2025 number at $252.1 million, up 89.83% from a year prior.
  • Tax Provisions was $73.4 million for Q4 2025 at Dexcom, up from $68.5 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $119.7 million in Q3 2023 to a low of -$61.2 million in Q1 2022.
  • A 5-year average of $31.9 million and a median of $42.1 million in 2022 define the central range for Tax Provisions.
  • Biggest YoY gain for Tax Provisions was 18800.0% in 2021; the steepest drop was 708.0% in 2021.
  • Dexcom's Tax Provisions stood at $11.7 million in 2021, then soared by 253.85% to $41.4 million in 2022, then plummeted by 124.4% to -$10.1 million in 2023, then surged by 690.1% to $59.6 million in 2024, then increased by 23.15% to $73.4 million in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Tax Provisions are $73.4 million (Q4 2025), $68.5 million (Q3 2025), and $61.3 million (Q2 2025).